

## Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

MARINA DEL REY, Calif., May 31, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced an oral presentation on the company's recently completed Phase 1b/2a SWARM-*P.a.* clinical trial at the 6<sup>th</sup> World Conference on Targeting Phage Therapy, which is being held June 1-2, 2023, in Paris.

The SWARM-*P.a.* trial was a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study that evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Armata's lead clinical bacteriophage candidate, AP-PA02, in patients with cystic fibrosis and chronic pulmonary *Pseudomonas aeruginosa* infection. Armata announced [positive topline data](#) from the trial in March 2023.

Details of the presentation are as follows:

**Title:** Safety, Pharmacokinetics, and Antibacterial Activity of AP-PA02 Multi-phage Cocktail in Patients with Cystic Fibrosis and Chronic Pulmonary *Pseudomonas aeruginosa* Infection (SWARM-*P.a.* Clinical Trial)  
**Presenter:** Mina Pastagia, MD, MS, Chief Medical Officer, Armata Pharmaceuticals  
**Session:** Session 5 - Phage Therapy: Towards Amplification and Innovation  
**Date:** June 2, 2023  
**Time:** 10:50 a.m. CEST (4:50 a.m. EDT)

For more information: <https://phagetherapy-site.com/>

### About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and other pathogens. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

### Media Contacts:

#### At Armata:

Pierre Kyme  
Armata Pharmaceuticals, Inc.  
[ir@armatapharma.com](mailto:ir@armatapharma.com)  
310-665-2928 x234

### Investor Relations:

Joyce Allaire  
LifeSci Advisors, LLC  
[jallaire@lifesciadvisors.com](mailto:jallaire@lifesciadvisors.com)  
212-915-2569

SOURCE Armata Pharmaceuticals, Inc.

---

<https://investor.armatapharma.com/2023-05-31-Armata-Pharmaceuticals-Announces-Oral-Presentation-Detailing-Results-from-the-Phase-1b-2a-SWARM-P-a-Clinical-Trial-at-the-6th-World-Conference-on-Targeting-Phage-Therapy>